APTA vs. OBI, SAR, POLB, OKYO, AREC, AOR, OPTI, IMM, RLM, and NSCI
Should you be buying Aptamer Group stock or one of its competitors? The main competitors of Aptamer Group include Ondine Biomedical (OBI), Sareum (SAR), Poolbeg Pharma (POLB), OKYO Pharma (OKYO), Arecor Therapeutics (AREC), AorTech International (AOR), OptiBiotix Health (OPTI), ImmuPharma (IMM), Realm Therapeutics (RLM), and NetScientific (NSCI). These companies are all part of the "biotechnology" industry.
Aptamer Group vs.
Aptamer Group (LON:APTA) and Ondine Biomedical (LON:OBI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.
Ondine Biomedical received 1 more outperform votes than Aptamer Group when rated by MarketBeat users.
Aptamer Group's return on equity of -187.53% beat Ondine Biomedical's return on equity.
11.7% of Aptamer Group shares are owned by institutional investors. Comparatively, 20.6% of Ondine Biomedical shares are owned by institutional investors. 13.2% of Aptamer Group shares are owned by insiders. Comparatively, 36.7% of Ondine Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Aptamer Group's average media sentiment score of 0.00 equaled Ondine Biomedical'saverage media sentiment score.
Aptamer Group has a beta of -0.52, meaning that its share price is 152% less volatile than the S&P 500. Comparatively, Ondine Biomedical has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500.
Aptamer Group has higher earnings, but lower revenue than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.
Summary
Ondine Biomedical beats Aptamer Group on 7 of the 11 factors compared between the two stocks.
Get Aptamer Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for APTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptamer Group Competitors List
Related Companies and Tools
This page (LON:APTA) was last updated on 1/22/2025 by MarketBeat.com Staff
